GenCC GmbH is focusing on utilizing the popular genome-editing tool CRISPR/Cas for cancer therapy. Due to the major advances in gene editing (e.g. CRISPR / Cas 9), and molecular tumor profiling of different types of cancer in recent years, personalized cancer therapy is increasingly becoming the focus of attention in cancer research.

The theoretical framework of the project has been already designed and developed. Experiments for the initial proof-of-concept will be performed in B-cell lymphomas which can be done in a laboratory with security level 1. In this phase of the project, we are not aiming to test any cancer stem cells. After proving the basic feasibility of the approaches and submitting the payment we will reach the second phase of our project which further therapy and questions come into focus.